Lantern Pharma (LTRN) Net Cash Flow (2019 - 2026)

Lantern Pharma (LTRN) has reported Net Cash Flow for 8 consecutive years, with -$2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 553.46% year-over-year to -$2.2 million; the trailing twelve-month figure through Jun 2026 stood at -$4.4 million (up 36.41% YoY), and the FY2025 full-year result was -$3.1 million, up 78.29% from the prior year.
• Net Cash Flow retreated to -$2.2 million in Q2 2026 per LTRN's latest filing, from $477373.0 in the prior quarter.
• Across five years, Net Cash Flow topped out at $1.4 million in Q3 2025 and bottomed at -$5.4 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$2.8 million across 5 years, with a median of -$3.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow slumped 656.79% in 2025, then surged 142.01% in 2026.
• Over 5 years, Net Cash Flow stood at -$2.1 million in 2022, then slumped by 51.46% to -$3.1 million in 2023, then jumped by 83.24% to -$524533.0 in 2024, then plunged by 656.79% to -$4.0 million in 2025, then jumped by 43.35% to -$2.2 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$2.2 million, $477373.0, and -$4.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.